ClinicalTrials.Veeva

Menu
N

NRC Research Institute | Orange, CA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

KarXT
Rapastinel
Troriluzole
BHV-7000
Cariprazine
Risperidone
Iclepertin
RVT-3101
Brexpiprazole
BI 425809

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 67 total trials

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of MK-2214 in adults with mild cognitive...

Enrolling
Alzheimer Disease
Drug: Placebo
Biological: MK-2214

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequ...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo

This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did...

Enrolling
Depressive Disorder, Major
Drug: BI 1569912
Drug: Placebo

This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of t...

Enrolling
Schizophrenia
Drug: Iclepertin

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Invitation-only
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

This is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in d...

Active, not recruiting
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I.

Enrolling
Bipolar Disorder
Drug: Placebo
Drug: BHV-7000

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000 in subjects with bipolar I disorder.

Invitation-only
Bipolar Disorder
Drug: BHV-7000

This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Example...

Active, not recruiting
Schizophrenia
Drug: Placebo
Drug: Iclepertin

The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compul...

Enrolling
Obsessive-Compulsive Disorder
Drug: Placebo
Drug: Troriluzole

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Enrolling
Agitation in Patients With Dementia of the Alzheimer's Type
Drug: AVP-786

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

ML-004-002 is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study that will enroll approximately 150 adolescent and ad...

Enrolling
Autism Spectrum Disorder
Drug: ML-004 Placebo
Drug: ML-004 (IR)/(ER) tablet

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RVT-3101 in a...

Active, not recruiting
Crohn Disease
Drug: RVT-3101

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RVT-3101 in a...

Active, not recruiting
Crohn Disease
Drug: RVT-3101

This is an open-label, parallel-group study to evaluate the safety and efficacy of ropanicant in participants with moderate to severe Major Depressiv...

Active, not recruiting
Major Depressive Disorder
Drug: Ropanicant

The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive d...

Active, not recruiting
Obsessive-Compulsive Disorder
Drug: Troriluzole
Drug: Placebo

Trial sponsors

Karuna Therapeutics logo
Boehringer Ingelheim logo
Roche logo
Allergan logo
Otsuka logo
Biohaven logo
Pfizer logo
Janssen (J&J Innovative Medicine) logo
AbbVie logo
Acadia Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems